San Diego CA/January 21, 2021–(PRNEWS WIRE)—NEUVOGEN todayannounced that Todd Binder, Chief Executive Officer of NEUVOGEN, will participate in the B. Riley Virtual Oncology Investor Conference:
B. Riley Virtual Oncology Investor Conference
Date: Thursday, January 21, 2021
Time: 3:00 PM Eastern Time
About NEUVOGEN
NEUVOGEN, Inc. is an immunoncology company focused on whole cell cancer vaccine therapies. NEUVOGEN’s immunotherapies have the potential to deliver the broadest ever combination of tumor antigens to prime immune response. Based in San Diego, California, NEUVOGEN’s goal is to bring to market a pipeline of therapeutic cancer vaccines that activate the body’s immune system to eradicate solid tumors and meaningfully extend the lives of patients while limiting side effects generally associated with traditional cancer treatments. To learn more, visit www.neuvogen.com
NEUVOGEN Contact:
Cyrus Arman
Vice President, Corporate Development and Strategy